Exploring novel KDR inhibitors based on pharmaco-informatics methodology

SAR and QSAR in Environmental Research

Volumn 24, Issue 3, 2013, Pages 215-234

  Kar, R K ^a,b   Suryadevara, P ^a,b   Sahoo, B R ^a   Sahoo, G C ^a   Dikhit, M R ^a   Das, P ^a,b  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^b National Institute of Pharmaceutical Education and Research (NIPER)   (India)

Author keywords

3D QSAR; docking; MD simulation; pharmacophore; virtual screening

Indexed keywords

COMPUTATIONAL CHEMISTRY; DIAGNOSIS; ENDOTHELIAL CELLS; METABOLISM; MOLECULAR GRAPHICS; PHARMACODYNAMICS; UREA;

3D-QSAR; ACTIVE SITE; DOCKING; ENDOTHELIAL-CELLS; INFORMATICS; MD SIMULATION; PHARMACOPHORES; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP (3D QSAR); VASCULAR ENDOTHELIAL GROWTH FACTOR; VIRTUAL SCREENING;

MOLECULES;

EID: 84875224352     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2013.765912     Document Type: Article

References (65)

1. Ferrara, N. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol., 280: C1358-C1366.
2. Pugh, C.W. and Ratcliffe, P.J. 2003. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Med., 9: 677-684.
3. Ferrara, N. 1999. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Intern., 56: 794-814.
4. Carmeliet, P. and Jain, R.K. 2000. Angiogenesis in cancer and other diseases. Nature, 407: 249-257.
5. Schneider, B.P. and Miller, K.D. 2005. Angiogenesis of breast cancer. J. Clin. Oncol., 23: 1782-1790.
6. Khurana, R., Simons, M., Martin, J.F. and Zachary, I.C. 2005. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation, 112: 1813-1824.
7. Lee, J.S., Semela, D., Iredale, J. and Shah, V.H. 2007. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte?. Hepatology, 45: 817-825.
8. Kirka, S., Frank, J.A. and Karlik, S. 2004. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J. Neurol. Sci., 217: 125-130.
9. Koutroubakis, I.E., Tsiolakidou, G., Karmiris, K. and Kouroumalis, E.A. 2006. Role of angiogenesis in inflammatory bowel disease. Inflamm. Bowel Dis., 12: 515-523.
10. Paleolog, E.M. and Fava, R.A. 1998. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin. Immunopathol., 20: 73-94.
11. Clapp, C., Thebault, S., Jeziorski, M.C. and Escalera, G.M. 2009. Peptide hormone regulation of angiogenesis. Physiol. Rev., 89: 1177-1215.
12. Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology, 69: 4-10.
13. Tournaire, R.B., Demange, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouret, J., Derbin, C., Perret, G. and Mazie, J.C. 2000. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J., 19: 1525-33.
14. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N. and Alitalo, K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15: 290-298.
15. Hanrahan, V., Currie, M.J., Gunningham, S.P., Morrin, H.R., Scott, P.A., Robinson, B.A. and Fox, S.B. 2003. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol., 200: 183-194.
16. Joukov, V., Sorsa, T., Kumar, V., Jelrsch, M., Welsh, L.C., Cao, Y., Saksela, O., Kalkkinen, N. and Alitalo, K. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J., 16: 3898-3911.
17. Ellis, L.M. and Hicklin, D.J. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev., 8: 579-591.
18. Kendall, R.L., Rutledge, R.Z., Mao, X., Tebben, A.J., Hungate, R.W. and Thomas, K.A. 1999. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J. Biol. Chem., 274: 6453-6460.
19. Antonescu, C.R., Yoshida, A. and Guo, T. 2009. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res., 69: 7175-7179.
20. Pander, J., Gelderblom, H. and Guchelaar, H. 2007. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov. Today, 12: 1054-1060.
21. X.J. Ma, S. Dahiya, E. Richardson, M. Erlander, and D. C. Sgroi, Gene expression profiling of the tumor microenvironment during breast cancer progression, Breast Cancer Res. 11 (2009):R7.
22. Huang, Y., Reyniès, A., Leval, L., Ghazi, B., Garcia, N., Travert, M., Bosq, J., Brière, J., Petit, B., Thomas, E., Coppo, P., Marafioti, T., Emile, J.F., Larue, M.D., Schmitt, C. and Gaulard, P. 2010. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 115: 1226-1237.
23. Manley, P.J., Balitza, A.E., Bilodeau, M.T., Coll, K.E., Hartman, G.D., McFall, R.C., Rickert, K.W., Rodman, L.D. and Thomas, K.A. 2003. 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors. Bioorg. Med. Chem. Lett., 13: 1673-1677.
24. Dai, Y., Hartandi, K., Soni, N.B., Pease, L.J., Reuter, D.R., Olson, A.M., Osterling, D.J., Doktor, S.Z., Albert, D.H., Bouska, J.J., Glaser, K.B., Marcotte, P.A., Stewart, K.D., Davidsen, S.K. and Michaelides, M.R. 2008. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg. Med. Chem. Lett., 18: 386-390.
25. Kuethe, J.T., Wong, A., Qu, C., Smitrovich, J., Davies, I.W. and Hughes, D.L. 2004. Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: A novel class of KDR kinase inhibitors. J. Org. Chem., 70: 2555-2567.
26. Kiselyov, A.S., Semenova, M., Semenovc, V.V. and Piatnitski, E. 2006. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: Novel dual inhibitors of VEGFR-1/2 kinases. Bioorg. Med. Chem. Lett., 16: 1726-1730.
27. Dinges, J., Zanze, I.A., Arnold, L.D., Bousquet, F., Cunha, G.A., Ericsson, A.M., Iwasaki, N., Michaelides, M.R., Ogawa, N., Phelan, K.M., Rafferty, P., Sowin, T.J., Stewart, K.D., Tokuyama, R., Xiaa, Z. and Zhang, H.Q. 2006. Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. Bioorg. Med. Chem. Lett., 16: 4371-4375.
28. Baindur, N., Chadha, N., Brandt, B.M., Asgari, D., Patch, R.J., Schalk, C., Carver, T.E., Petrounia, I.P., Baumann, C.A., Ott, H., Manthey, C., Springer, B.A. and Player, M.R. 2005. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: A novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors. J. Med. Chem., 48: 1717-1720.
29. Cristofanilli, M., Charnsangavej, C. and Hortobagyi, G.N. 2002. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev., 1: 415-426.
30. Pien, H.H., Fischman, A.J., Thrall, J.H. and Sorensen, A.G. 2005. Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today, 10: 259-266.
31. Morabito, A., Piccirillo, M.C., Falasconi, F., Feo, G.D., Giudice, A.D., Bryce, J., Maio, M.D., Maio, E.D., Normanno, N. and Perrone, F. 2009. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. The Oncologist, 14: 378-390.
32. Gauler, T.C., Besse, B., Mauguen, A., Meric, J.B., Gounant, V., Fischer, B., Overbeck, T.R., Krissel, H., Laurent, D., Tiainen, M., Commo, F., Soria, J.C. and Eberhardt, W.E.E. 2012. Phase II trial of PTK787/ZK 222584 (Vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann. Oncol., 23: 678-687.
33. M.I. El-Gamal, H.S. Anbar, K.H. Yoo, and C.H. Oh, FMS kinase inhibitors: Current status and future prospects, Med. Res. Rev. (2012), DOI 10.1002.
34. Asahina, H., Tamura, Y., Nokihara, H., Yamamoto, N., Seki, Y., Shibata, T., Goto, Y., Tanioka, M., Yamada, Y., Coates, A., Chiu, Y.L., Li, Xiaohui, Pradhan, R., Ansell, P. J., McKeegan, E. M., McKee, M. D., Carlson, D. M. and Tamura, T. 2012. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother. Pharmacol., 69: 1477-1486.
35. Gracias, V., Ji, Z., Zanze, I.A., Zapatero, C.A., Huth, J.R., Song, D., Hajduk, P.J., Johnson, E.F., Glaser, K.B., Marcotte, P.A., Pease, L., Soni, N.B., Stewart, K.D., Davidsen, S.K., Michaelides, M.R. and Djuric, S.W. 2008. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 18: 2691-2695.
36. Ji, Z., Ahmed, A.A., Albert, D.H., Bouska, J.J., Bousquet, P.F., Cunha, G.A., Diaz, G., Glaser, K.B., Guo, J., Harris, C.M., Li, J., Marcotte, P.A., Moskey, M.D., Oie, T., Pease, L., Soni, N.B., Stewart, K.D., Davidsen, S.K. and Michaelides, M.R. 2008. 3-Amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. J. Med. Chem., 51: 1231-1241.
37. Zanzel, A., Albert, D.H., Bousquet, P.F., Cunha, G.A., Harris, C.M., Moskey, M., Dinges, J., Stewart, K.D. and Sowin, T.J. 2007. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 17: 3136-3140.
38. Cronin, M.T.D. and Schultz, T.W. 2003. Pitfalls in QSAR. J. Mol. Struc., 622: 39-51.
39. Phase, version 3.3, Schrödinger, LLC, New York, 2011.
40. Dixon, S.L., Smondyrev, A.M., Knoll, E.H., Rao, S.N., Shaw, D.E. and Friesner, R.A. 2006. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 20: 647-671.
41. Jorgensen, W.L. and Tirado, R.J. 1988. The OPLS force field for proteins. Energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc., 110: 1657-1666.
42. Watts, K.S., Dalal, P., Murphy, R.B., Sherman, W., Friesner, R.A. and Shelley, J.C. 2010. Confromational search method for efficient generation of bioactive conformers. J. Chem. Inf. Model., 50: 534-546.
43. Tropsha, A., Gramatica, P. and Gombar, V.K. 2003. The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci., 22: 69-77.
44. Gramatica, P. 2007. Principles of QSAR models validation: internal and external. QSAR Comb. Sci., 26: 694-701.
45. Hawkins, D.M., Basak, S.C. and Mills, D. 2003. Assessing model fit by cross-validation. J. Chem. Inf. Comput. Sci., 43: 579-586.
46. Guha, R. and Jurs, P.C. 2005. Determining the validity of a QSAR model - A classification approach. J. Chem. Inf. Model., 45: 65-73.
47. 2!. J. Mol. Graph. Model., 20: 269-276.
48. Consonni, V., Ballabio, D. and Todeschini, R. 2009. Comments on the definition of the Q2 parameter for QSAR validation. J. Chem. Inf. Model., 49: 1669-1678.
49. Kubinyi, H. 1997. QSAR and 3D QSAR in drug design Part 1: Methodology. Drug Discov. Today, 2: 457-467.
50. Kubinyi, H. 1997. QSAR and 3D QSAR in drug design Part 2: Applications and problems. Drug Discov. Today, 2: 538-546.
51. Golbraikh, A. and Tropsha, A. 2002. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J. Comput. Aided Mol. Des., 16: 357-369.
52. Doweyko, A.M. 2004. 3D-QSAR illusions. J. Comput. Aided Mol. Des., 18: 587-596.
53. Schuurmann, G., Ebert, R.U., Chen, J., Wang, B. and Kuhne, R. 2008. External validation and prediction employing the predictive squared correlation coefficients test set activity mean vs. training set activity mean. J. Chem. Inf. Model., 48: 2140-2145.
54. 2 as a metric for validation of QSAR models. J. Chemom., 24: 22-33.
55. Glide, version 5.7, Schrödinger, LLC, New York, 2011.
56. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P. and Shenkin, P.S. 2004. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 47: 1739-1749.
57. Miyazaki, Y., Matsunaga, S., Tang, J., Maeda, Y., Nakano, M., Philippe, R.J., Shibahara, M., Liu, W., Sato, H., Wangb, L. and Nolteb, R.T. 2005. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett., 15: 2203-2207.
58. Desmond Molecular Dynamics System, version 3.0, D.E. Shaw Research, New York, 2011.
59. Maestro-Desmond Interoperability Tools, version 3.0, Schrodinger, New York, 2011.
60. Mackerell, A.D., Bashford, D., Bellott, M., Dunbrack, R.L., Evanseck, J.D., Field, M.J., Fischer, S., Gao, J., Guo, H., Ha, S., McCarthy, D.J., Kuchnir, L., Kuczera, K., Lau, F.T.K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D.T., Prodhom, B., Reiher, W.E., Roux, B., Schlenkrich, M., Smith, J.C., Stote, R., Straub, J., Watanabe, M., Kuczera, W., Yin, D. and Karplus, M. 1998. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B, 102: 3586-3616.
61. Ryckaert, J.P., Ciccotti, G. and Berendsen, H.J.C. 1997. Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys., 23: 327-341.
62. Zeng, H. and Zhang, H. 2010. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors. J. Mol. Graph. Model., 29: 54-71.
63. Du, J., Lei, B., Qin, J., Liu, H. and Yao, X. 2009. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model., 27: 642-654.
64. Pasha, F.A., Muddassar, M., Neaz, M.M. and Cho, S.J. 2009. Pharmacophore and docking-based combined in-silico study of KDR inhibitors. J. Mol. Graph. Model., 28: 54-61.
65. Abreu, R.M.V., Froufe, H.J.C., Queiroz, M.R.P. and Ferreira, I.C.F.R. 2012. Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina. Chem. Biol. Drug Des., 79: 530-534.